Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12378323 | 0.94 | KEAP1 (0.33) | KEAP1NFE2L2KDM4E | |
| SCHEMBL13592618 | 0.93 | KEAP1 (0.34) | KEAP1NFE2L2KDM4E | |
| SCHEMBL12378300 | 0.92 | CYP19A1 (0.33) | KEAP1NFE2L2PDE1B | |
| SCHEMBL13592617 | 0.91 | KEAP1 (0.34) | KEAP1NFE2L2KDM4E | |
| SCHEMBL12378322 | 0.86 | HPGD (0.32) | — | |
| SCHEMBL12378273 | 0.86 | PDE1B (0.35) | PDE1BKDM4E | |
| SCHEMBL12378327 | 0.86 | CYP19A1 (0.34) | KEAP1NFE2L2KDM4E | |
| SCHEMBL12378328 | 0.86 | CYP19A1 (0.32) | KEAP1NFE2L2 | |
| SCHEMBL12378305 | 0.85 | CYP19A1 (0.34) | KEAP1NFE2L2PDE1B | |
| SCHEMBL12378542 | 0.85 | CYP19A1 (0.33) | KEAP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | KEAP1 4299/4885NFE2L2 4456/4885PDE1B 3694/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | KEAP1 4110/4885NFE2L2 3762/4885PDE1B 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.